CiMUS researchers participate in a new European project for antithrombotic drugs development
Members of the research groups Proteomics of Platelets and Biofarma will participate in a new European project aimed at the development of new antithrombotic drugs capable of inhibiting blood platelets.
Led by the CiMUS by Professor Ángel García (responsible for the Protease group of Plaquetas and president of the Spanish Society of Proteomics), the project will receive funding close to four million euros and will have the collaboration of institutions and companies of the Kingdom The United Kingdom, Germany and the Netherlands, with the most relevant European researchers in the field of platelet research.
Searching for new drugs against thrombosis
Patients at risk of thrombosis are treated with drugs that inhibit platelets, although many of them continue to suffer episodes related to this disease or hemorrhages, so there is a need to develop new drugs more effective and safe, the main objective of this project.
The initiative will also result in the creation of a European PhD program that will grant double degrees between participating universities. In total, it will train 15 doctoral students who will be hired in charge of the project and will receive first level training in this interdisciplinary area, which will allow them to acquire knowledge and skills that facilitate their professional incorporation into the world of biomedical research.